Genomic & Biopharma News

ORB relocates to Deerfield Beach and celebrates grand opening of new facility with local researchers
After 8 years of operation in Palm Beach Gardens, Ocean Ridge Biosciences (ORB) has recently relocated to a 5,394 sq. ft. facility in Deerfield Beach, Florida. The new facility provides several improvements which will enable ORB to provide improved and expanded services to academic and corporate clients. These include:
ORB Company Blog, 2016-11-21 19:26:55

JHU Researchers Harmed Dogs, Animal Rights Group Argues
Stop Animal Exploitation Now issues a federal complaint against Johns Hopkins scientists, saying they messed up surgeries on nine animals.
The Scientist, 2019-08-15 16:00:41

EuroBiotech Report—Autolus delay, Novartis sale, Sonnet deal, Y-mAbs and the U.K.
In this week's EuroBiotech Report, Autolus delays CAR-T trials, Novartis punts rare disease drug and Sonnet bags ex-Serono drug.
Fierce Biotech, 2019-08-15 15:47:42

High gluten intake during childhood increases risk of celiac disease
Children are more likely to develop celiac disease if they consume higher-than-average amounts of gluten during the first five years of life.
News Medical Life Sciences, 2019-08-15 15:47:00

EuroBiotech: More Articles of Note
In our EuroBiotech roundup this week, Lundbeck cans AF35700, AstronauTx bags cash for Alzheimer’s R&D and AC Immune forms research pact.
Fierce Biotech, 2019-08-15 15:40:44

Pelican Newspaper: Gene profiling at Ocean Ridge Biosciences to unlock mysteries of the human body
Identifying the markers for pancreatic cancer may have happened here in a 5,400 square foot facility where scientists routinely practice next generation RNA profiling and biomarker discovery. Please read the PDF for more details
ORB Company News, 2016-11-25 18:55:37

Machine learning reveals links between genetic factors and behavior
Researchers have used machine learning to start making links between seemingly instinctive, random behaviors and genetic factors.
News Medical Life Sciences, 2019-08-15 15:39:17

MacroGenics, Incyte's PD-1 med to face off with Merck's Keytruda in a first for cancer R&D
It has the makings of a David and Goliath story: MacroGenics will kick off a trial this year that will pit its Incyte-partnered anti-PD-1 drug against Merck’s Keytruda—the first drug of its class to win approval—in patients with head and neck cancer.
Fierce Biotech, 2019-08-15 15:23:46

How nematode worms could inspire safer opioid use
While looking for clues to reduce opioids’ toxic effects, scientists at the Scripps Research Institute built a research platform based on roundworms. They found a rare receptor they say might one day make opioid use safer.
Fierce Biotech, 2019-08-15 15:16:47

Sanofi defends top oncology drug with Jevtana patent win
Sanofi has been battling against generics companies over patents to Jevtana, its top oncology product. In the latest round, the company scored a win to defend a 2021 patent and a 2031 patent. The company convinced an appeals court to overturn a prior loss it suffered on a 2031 patent.
Fierce Pharma, 2019-08-15 14:53:14

Scientists find a potent weapon against antibiotic resistance
Antibiotic resistance is a big threat to global health, and a growing number of infections are now becoming harder to treat. The usual treatments, like antibiotics used to treat them, becomes less effective. Now, a team of researchers may have found a potent weapon against antibiotic-resistant bacteria, which can help treat persistent infections.
News Medical Life Sciences, 2019-08-15 14:41:52